Borker, Anupama and Choudhary, Narendra (2011) Rituximab. Indian Pediatrics, 48. pp. 627-632.

PDF Rituximab._IP_2011.pdf - Published Version Restricted to Registered users only Download (32kB) | Request a copy

Abstract

Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkin’s lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.

Item Type:	Article
Uncontrolled Keywords:	Rituximab, Monoclonal antibodies, CD20.
Subjects:	Medicine > KMC Manipal > Paediatrics
Depositing User:	KMC Manipal
Date Deposited:	19 Apr 2012 04:03
Last Modified:	19 Apr 2012 04:03
URI:	http://eprints.manipal.edu/id/eprint/76256

Actions (login required)

View Item